IDEXX Laboratories, Inc. vs Nano Dimension Ltd - ADR — how do they compare? IDEXX Laboratories, Inc. trades at $563.81 (market cap $44.48B), while Nano Dimension Ltd - ADR trades at $1.48 (market cap $322.08M). The key difference: IDEXX Laboratories, Inc. is far larger — about 138.1× Nano Dimension Ltd - ADR's market cap, and Nano Dimension Ltd - ADR is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| IDXX | NNDM | |
|---|---|---|
Market Cap | $44.48B | $322.08M |
Sector | Health | Technology |
52-Week High | $766.68 | $2.14 |
52-Week Low | $520.87 | $1.21 |
Enterprise Value | $45.38B | -$87.26M |
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories trades at $552.46, down 2.64% today, with neutral technical signals but strong fundamental performance. The company maintains robust profitability with 24.63% net margins and has beaten earnings expectations for three consecutive quarters. Recent news highlights AI integration in medical devices and upcoming Q2 2026 results on August 4, 2026. The stock shows consistent revenue growth from $3.4B in 2022 to $4.3B in 2025.
Outlook remains positive given earnings momentum and analyst consensus, though elevated valuation ratios (P/E 41.49) pose risks. Key catalysts include Q2 earnings release and continued AI adoption in veterinary diagnostics. Primary risks involve competitive pressures and market volatility affecting premium valuations.
Nano Dimension (NNDM) trades at $1.49, down 3.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $102.44 million in 2025 but a net loss of $293.30 million, reflecting a negative net income margin of 286.72%. Recent news highlights board changes, cost-saving initiatives, and a proposed business combination with Infinite Epigenetics.
The outlook remains challenging due to persistent losses and negative cash flow, though cost reductions and strategic moves aim to stabilize. Key risks include execution of the turnaround plan and shareholder disputes. Analyst sentiment is mixed, with the stock trading below book value, indicating potential value if operations improve.
Trailing returns across standard periods
Latest headlines on both assets
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →Nano Dimension Ltd is engaged in research and development of a three-dimensional printer that prints electronic circuit boards, also known as printed circuit boards, and ink materials and products based on nanotechnology. Its products consist of two main product lines - Dragonfly 2020 3D printer and proprietary ink products. The company's Dragonfly 2020 3D printer currently in development uses proprietary ink and integrated software to quickly create fully functioning PCB prototypes. Geographically, it generates maximum revenue from the USA followed by the Asia Pacific and Europe and Israel. It serves the Commercial, Research and Printing services industries.
Read more on NNDM →